Titre : Benzazépines

Benzazépines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Docetaxel

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dépendance aux benzazépines ?

Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs.
Dépendance aux médicaments Benzodiazépines
#2

Quels tests sont utilisés pour évaluer l'usage des benzazépines ?

Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés.
Tests de dépistage Benzodiazépines
#3

Quels critères DSM sont liés aux benzazépines ?

Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines.
Trouble d'usage de substances Benzodiazépines
#4

Comment évaluer les effets secondaires des benzazépines ?

L'évaluation se fait par l'observation des symptômes et l'historique médical du patient.
Effets secondaires Benzodiazépines
#5

Quels signes indiquent une surdose de benzazépines ?

Les signes incluent confusion, somnolence excessive, et dépression respiratoire.
Surdose Benzodiazépines

Symptômes 5

#1

Quels sont les symptômes d'une surconsommation de benzazépines ?

Les symptômes incluent somnolence, confusion, et troubles de la coordination.
Symptômes Benzodiazépines
#2

Comment se manifeste le sevrage des benzazépines ?

Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions.
Sevrage Benzodiazépines
#3

Quels effets à long terme des benzazépines ?

Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance.
Effets à long terme Benzodiazépines
#4

Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?

Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil.
Anxiété Benzodiazépines
#5

Les benzazépines causent-elles des troubles de la mémoire ?

Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose.
Troubles de la mémoire Benzodiazépines

Prévention 5

#1

Comment prévenir la dépendance aux benzazépines ?

Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives.
Prévention Dépendance aux médicaments
#2

Quelles sont les recommandations pour l'utilisation des benzazépines ?

Utiliser à la dose minimale efficace et pour la durée la plus courte possible.
Recommandations Benzodiazépines
#3

Comment éduquer les patients sur les benzazépines ?

Informer sur les risques, les effets secondaires et l'importance du suivi médical.
Éducation des patients Benzodiazépines
#4

Quels sont les risques d'auto-médication avec des benzazépines ?

L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses.
Auto-médication Benzodiazépines
#5

Comment réduire l'usage des benzazépines dans la population ?

Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés.
Réduction de l'usage Benzodiazépines

Traitements 5

#1

Comment sont prescrites les benzazépines ?

Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines.
Prescription Benzodiazépines
#2

Quelles alternatives aux benzazépines pour l'anxiété ?

Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives.
Antidépresseurs Anxiété
#3

Comment gérer une overdose de benzazépines ?

L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil.
Overdose Benzodiazépines
#4

Les benzazépines sont-elles efficaces pour l'insomnie ?

Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires.
Insomnie Benzodiazépines
#5

Quel suivi est nécessaire lors de l'utilisation de benzazépines ?

Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires.
Suivi médical Benzodiazépines

Complications 5

#1

Quelles complications peuvent survenir avec les benzazépines ?

Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence.
Complications Benzodiazépines
#2

Les benzazépines augmentent-elles le risque de chutes ?

Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées.
Chutes Benzodiazépines
#3

Comment les benzazépines affectent-elles la respiration ?

Elles peuvent déprimer le système respiratoire, surtout en cas de surdose.
Dépression respiratoire Benzodiazépines
#4

Les benzazépines peuvent-elles interagir avec d'autres médicaments ?

Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs.
Interactions médicamenteuses Benzodiazépines
#5

Quels sont les effets des benzazépines sur la grossesse ?

Elles peuvent causer des malformations congénitales et des complications néonatales.
Grossesse Benzodiazépines

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de dépendance aux benzazépines ?

Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque.
Dépendance Benzodiazépines
#2

Les personnes âgées sont-elles plus à risque avec les benzazépines ?

Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes.
Personnes âgées Benzodiazépines
#3

Comment l'usage prolongé de benzazépines affecte-t-il le risque ?

L'usage prolongé augmente le risque de dépendance et de troubles cognitifs.
Usage prolongé Benzodiazépines
#4

Quels facteurs psychologiques influencent l'usage des benzazépines ?

L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines.
Facteurs psychologiques Benzodiazépines
#5

Les interactions médicamenteuses augmentent-elles les risques ?

Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents.
Interactions médicamenteuses Benzodiazépines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzazépines : Questions médicales les plus fréquentes", "headline": "Benzazépines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzazépines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétérobicycliques", "url": "https://questionsmedicales.fr/mesh/D006574", "about": { "@type": "MedicalCondition", "name": "Composés hétérobicycliques", "code": { "@type": "MedicalCode", "code": "D006574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Benzodiazépines", "alternateName": "Benzodiazepines", "url": "https://questionsmedicales.fr/mesh/D001569", "about": { "@type": "MedicalCondition", "name": "Benzodiazépines", "code": { "@type": "MedicalCode", "code": "D001569", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alprazolam", "alternateName": "Alprazolam", "url": "https://questionsmedicales.fr/mesh/D000525", "about": { "@type": "MedicalCondition", "name": "Alprazolam", "code": { "@type": "MedicalCode", "code": "D000525", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.030" } } }, { "@type": "MedicalWebPage", "name": "Benzodiazépinones", "alternateName": "Benzodiazepinones", "url": "https://questionsmedicales.fr/mesh/D001570", "about": { "@type": "MedicalCondition", "name": "Benzodiazépinones", "code": { "@type": "MedicalCode", "code": "D001570", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } } ] }, { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } }, { "@type": "MedicalWebPage", "name": "Chlordiazépoxyde", "alternateName": "Chlordiazepoxide", "url": "https://questionsmedicales.fr/mesh/D002707", "about": { "@type": "MedicalCondition", "name": "Chlordiazépoxyde", "code": { "@type": "MedicalCode", "code": "D002707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.150" } } }, { "@type": "MedicalWebPage", "name": "Clobazam", "alternateName": "Clobazam", "url": "https://questionsmedicales.fr/mesh/D000078306", "about": { "@type": "MedicalCondition", "name": "Clobazam", "code": { "@type": "MedicalCode", "code": "D000078306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.165" } } }, { "@type": "MedicalWebPage", "name": "Clorazépate dipotassique", "alternateName": "Clorazepate Dipotassium", "url": "https://questionsmedicales.fr/mesh/D003009", "about": { "@type": "MedicalCondition", "name": "Clorazépate dipotassique", "code": { "@type": "MedicalCode", "code": "D003009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.180" } } }, { "@type": "MedicalWebPage", "name": "Estazolam", "alternateName": "Estazolam", "url": "https://questionsmedicales.fr/mesh/D004949", "about": { "@type": "MedicalCondition", "name": "Estazolam", "code": { "@type": "MedicalCode", "code": "D004949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.250" } } }, { "@type": "MedicalWebPage", "name": "Médazépam", "alternateName": "Medazepam", "url": "https://questionsmedicales.fr/mesh/D008472", "about": { "@type": "MedicalCondition", "name": "Médazépam", "code": { "@type": "MedicalCode", "code": "D008472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.550" } } }, { "@type": "MedicalWebPage", "name": "Midazolam", "alternateName": "Midazolam", "url": "https://questionsmedicales.fr/mesh/D008874", "about": { "@type": "MedicalCondition", "name": "Midazolam", "code": { "@type": "MedicalCode", "code": "D008874", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.575" } } }, { "@type": "MedicalWebPage", "name": "Olanzapine", "alternateName": "Olanzapine", "url": "https://questionsmedicales.fr/mesh/D000077152", "about": { "@type": "MedicalCondition", "name": "Olanzapine", "code": { "@type": "MedicalCode", "code": "D000077152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.738" } } }, { "@type": "MedicalWebPage", "name": "Triazolam", "alternateName": "Triazolam", "url": "https://questionsmedicales.fr/mesh/D014229", "about": { "@type": "MedicalCondition", "name": "Triazolam", "code": { "@type": "MedicalCode", "code": "D014229", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Diltiazem", "alternateName": "Diltiazem", "url": "https://questionsmedicales.fr/mesh/D004110", "about": { "@type": "MedicalCondition", "name": "Diltiazem", "code": { "@type": "MedicalCode", "code": "D004110", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.150" } } }, { "@type": "MedicalWebPage", "name": "Fénoldopam", "alternateName": "Fenoldopam", "url": "https://questionsmedicales.fr/mesh/D018818", "about": { "@type": "MedicalCondition", "name": "Fénoldopam", "code": { "@type": "MedicalCode", "code": "D018818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.300" } } }, { "@type": "MedicalWebPage", "name": "Galantamine", "alternateName": "Galantamine", "url": "https://questionsmedicales.fr/mesh/D005702", "about": { "@type": "MedicalCondition", "name": "Galantamine", "code": { "@type": "MedicalCode", "code": "D005702", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.525" } } }, { "@type": "MedicalWebPage", "name": "Ivabradine", "alternateName": "Ivabradine", "url": "https://questionsmedicales.fr/mesh/D000077550", "about": { "@type": "MedicalCondition", "name": "Ivabradine", "code": { "@type": "MedicalCode", "code": "D000077550", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.801" } } }, { "@type": "MedicalWebPage", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "alternateName": "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine", "url": "https://questionsmedicales.fr/mesh/D015647", "about": { "@type": "MedicalCondition", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "code": { "@type": "MedicalCode", "code": "D015647", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.838" } } }, { "@type": "MedicalWebPage", "name": "Tolvaptan", "alternateName": "Tolvaptan", "url": "https://questionsmedicales.fr/mesh/D000077602", "about": { "@type": "MedicalCondition", "name": "Tolvaptan", "code": { "@type": "MedicalCode", "code": "D000077602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzazépines", "alternateName": "Benzazepines", "code": { "@type": "MedicalCode", "code": "D001552", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Bernhard Wünsch", "url": "https://questionsmedicales.fr/author/Bernhard%20W%C3%BCnsch", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany." } }, { "@type": "Person", "name": "Dirk Schepmann", "url": "https://questionsmedicales.fr/author/Dirk%20Schepmann", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany." } }, { "@type": "Person", "name": "Simon M Ametamey", "url": "https://questionsmedicales.fr/author/Simon%20M%20Ametamey", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch." } }, { "@type": "Person", "name": "Nadine Ritter", "url": "https://questionsmedicales.fr/author/Nadine%20Ritter", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de." } }, { "@type": "Person", "name": "Guiscard Seebohm", "url": "https://questionsmedicales.fr/author/Guiscard%20Seebohm", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The interactions of docetaxel with tumor microenvironment.", "datePublished": "2023-04-29", "url": "https://questionsmedicales.fr/article/37126985", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.intimp.2023.110214" } }, { "@type": "ScholarlyArticle", "name": "Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer.", "datePublished": "2023-02-02", "url": "https://questionsmedicales.fr/article/36727271", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cnr2.1793" } }, { "@type": "ScholarlyArticle", "name": "Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy.", "datePublished": "2023-05-22", "url": "https://questionsmedicales.fr/article/37218162", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10781552231177597" } }, { "@type": "ScholarlyArticle", "name": "Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.", "datePublished": "2022-06-29", "url": "https://questionsmedicales.fr/article/35767376", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/pros.24406" } }, { "@type": "ScholarlyArticle", "name": "Wounding the stroma: Docetaxel's role in dormant breast cancer escape.", "datePublished": "2023-09-13", "url": "https://questionsmedicales.fr/article/37703292", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pbio.3002297" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzazépines", "item": "https://questionsmedicales.fr/mesh/D001552" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzazépines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzazépines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzazépines", "description": "Comment diagnostiquer une dépendance aux benzazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzazépines ?\nQuels critères DSM sont liés aux benzazépines ?\nComment évaluer les effets secondaires des benzazépines ?\nQuels signes indiquent une surdose de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Docetaxel#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzazépines", "description": "Quels sont les symptômes d'une surconsommation de benzazépines ?\nComment se manifeste le sevrage des benzazépines ?\nQuels effets à long terme des benzazépines ?\nQuels symptômes d'anxiété peuvent être soulagés par les benzazépines ?\nLes benzazépines causent-elles des troubles de la mémoire ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Docetaxel#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzazépines", "description": "Comment prévenir la dépendance aux benzazépines ?\nQuelles sont les recommandations pour l'utilisation des benzazépines ?\nComment éduquer les patients sur les benzazépines ?\nQuels sont les risques d'auto-médication avec des benzazépines ?\nComment réduire l'usage des benzazépines dans la population ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Docetaxel#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzazépines", "description": "Comment sont prescrites les benzazépines ?\nQuelles alternatives aux benzazépines pour l'anxiété ?\nComment gérer une overdose de benzazépines ?\nLes benzazépines sont-elles efficaces pour l'insomnie ?\nQuel suivi est nécessaire lors de l'utilisation de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Docetaxel#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzazépines", "description": "Quelles complications peuvent survenir avec les benzazépines ?\nLes benzazépines augmentent-elles le risque de chutes ?\nComment les benzazépines affectent-elles la respiration ?\nLes benzazépines peuvent-elles interagir avec d'autres médicaments ?\nQuels sont les effets des benzazépines sur la grossesse ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Docetaxel#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzazépines", "description": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?\nLes personnes âgées sont-elles plus à risque avec les benzazépines ?\nComment l'usage prolongé de benzazépines affecte-t-il le risque ?\nQuels facteurs psychologiques influencent l'usage des benzazépines ?\nLes interactions médicamenteuses augmentent-elles les risques ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Docetaxel#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance aux benzazépines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'usage des benzazépines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels critères DSM sont liés aux benzazépines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des benzazépines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par l'observation des symptômes et l'historique médical du patient." } }, { "@type": "Question", "name": "Quels signes indiquent une surdose de benzazépines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence excessive, et dépression respiratoire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une surconsommation de benzazépines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent somnolence, confusion, et troubles de la coordination." } }, { "@type": "Question", "name": "Comment se manifeste le sevrage des benzazépines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions." } }, { "@type": "Question", "name": "Quels effets à long terme des benzazépines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance." } }, { "@type": "Question", "name": "Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil." } }, { "@type": "Question", "name": "Les benzazépines causent-elles des troubles de la mémoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose." } }, { "@type": "Question", "name": "Comment prévenir la dépendance aux benzazépines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives." } }, { "@type": "Question", "name": "Quelles sont les recommandations pour l'utilisation des benzazépines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser à la dose minimale efficace et pour la durée la plus courte possible." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les benzazépines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Informer sur les risques, les effets secondaires et l'importance du suivi médical." } }, { "@type": "Question", "name": "Quels sont les risques d'auto-médication avec des benzazépines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses." } }, { "@type": "Question", "name": "Comment réduire l'usage des benzazépines dans la population ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés." } }, { "@type": "Question", "name": "Comment sont prescrites les benzazépines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines." } }, { "@type": "Question", "name": "Quelles alternatives aux benzazépines pour l'anxiété ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives." } }, { "@type": "Question", "name": "Comment gérer une overdose de benzazépines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil." } }, { "@type": "Question", "name": "Les benzazépines sont-elles efficaces pour l'insomnie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires." } }, { "@type": "Question", "name": "Quel suivi est nécessaire lors de l'utilisation de benzazépines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les benzazépines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence." } }, { "@type": "Question", "name": "Les benzazépines augmentent-elles le risque de chutes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Comment les benzazépines affectent-elles la respiration ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent déprimer le système respiratoire, surtout en cas de surdose." } }, { "@type": "Question", "name": "Les benzazépines peuvent-elles interagir avec d'autres médicaments ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs." } }, { "@type": "Question", "name": "Quels sont les effets des benzazépines sur la grossesse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent causer des malformations congénitales et des complications néonatales." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque avec les benzazépines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes." } }, { "@type": "Question", "name": "Comment l'usage prolongé de benzazépines affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé augmente le risque de dépendance et de troubles cognitifs." } }, { "@type": "Question", "name": "Quels facteurs psychologiques influencent l'usage des benzazépines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines." } }, { "@type": "Question", "name": "Les interactions médicamenteuses augmentent-elles les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 09/05/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

31 au total
└─

Benzodiazépines

Benzodiazepines D001569 - D03.633.100.079.080
└─

Diltiazem

Diltiazem D004110 - D03.633.100.079.150
└─

Fénoldopam

Fenoldopam D018818 - D03.633.100.079.300
└─

Galantamine

Galantamine D005702 - D03.633.100.079.525
└─

Ivabradine

Ivabradine D000077550 - D03.633.100.079.801
└─

1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine D015647 - D03.633.100.079.838
└─

Tolvaptan

Tolvaptan D000077602 - D03.633.100.079.875
└─└─

Alprazolam

Alprazolam D000525 - D03.633.100.079.080.030
└─└─

Benzodiazépinones

Benzodiazepinones D001570 - D03.633.100.079.080.070
└─└─

Chlordiazépoxyde

Chlordiazepoxide D002707 - D03.633.100.079.080.150
└─└─

Clobazam

Clobazam D000078306 - D03.633.100.079.080.165
└─└─

Clorazépate dipotassique

Clorazepate Dipotassium D003009 - D03.633.100.079.080.180
└─└─

Estazolam

Estazolam D004949 - D03.633.100.079.080.250
└─└─

Médazépam

Medazepam D008472 - D03.633.100.079.080.550
└─└─

Midazolam

Midazolam D008874 - D03.633.100.079.080.575
└─└─

Olanzapine

Olanzapine D000077152 - D03.633.100.079.080.738
└─└─

Triazolam

Triazolam D014229 - D03.633.100.079.080.900
└─└─└─

Bromazépam

Bromazepam D001960 - D03.633.100.079.080.070.110
└─└─└─

Clonazépam

Clonazepam D002998 - D03.633.100.079.080.070.150
└─└─└─

Dévazépide

Devazepide D020109 - D03.633.100.079.080.070.200
└─└─└─

Diazépam

Diazepam D003975 - D03.633.100.079.080.070.216
└─└─└─

Flumazénil

Flumazenil D005442 - D03.633.100.079.080.070.305
└─└─└─

Flunitrazépam

Flunitrazepam D005445 - D03.633.100.079.080.070.320
└─└─└─

Flurazépam

Flurazepam D005479 - D03.633.100.079.080.070.348
└─└─└─

Lorazépam

Lorazepam D008140 - D03.633.100.079.080.070.450
└─└─└─

Nitrazépam

Nitrazepam D009567 - D03.633.100.079.080.070.565
└─└─└─

Oxazépam

Oxazepam D010076 - D03.633.100.079.080.070.663
└─└─└─

Pirenzépine

Pirenzepine D010890 - D03.633.100.079.080.070.750
└─└─└─

Prazépam

Prazepam D011222 - D03.633.100.079.080.070.784
└─└─└─

Témazépam

Temazepam D013693 - D03.633.100.079.080.070.880
└─└─└─└─

Nordazépam

Nordazepam D003708 - D03.633.100.079.080.070.216.500

Auteurs principaux

Bernhard Wünsch

9 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.

Dirk Schepmann

7 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.

Simon M Ametamey

5 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch.
Publications dans "Benzazépines" :

Nadine Ritter

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
  • Chembion, University of Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.

Guiscard Seebohm

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.

Alexander Markus

3 publications dans cette catégorie

Affiliations :
  • Institut für Pharmazeutische und Medizinische Chemie der Universität Münster, Münster, Germany.

Paul Disse

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.

Julian A Schreiber

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nathalie Strutz-Seebohm

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.

Nengneng Zhou

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Fangli Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Lei Wang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Xiang Gao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Xiaowei Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Man Zhang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Álvaro Velasco-Rubio

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Jesús A Varela

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Carlos Saá

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Yoshikazu Arai

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: arai.yoshikazu.mh@daiichisankyo.co.jp.

Yohei Kiyotsuka

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

Sources (804 au total)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer.

Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However,... Twenty-two patients with recurrent NSCLC who received DTX + RAM therapy at the Hiroshima Prefectural Hospital. The cut-off value which is the most unlikely to cause FN without the combined use of pegf... Pegfilgrastim can be discontinued when the dose of DTX is reduced to <48 mg/m...

Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy.

Posterior reversible encephalopathy syndrome is a clinical and imaging syndrome characterized by endothelial dysfunction, blood-brain barrier disruption, and vasogenic edema. The common clinical sympt... We describe the case of a middle-aged woman with gastric cancer. She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progre... After admission, she was treated to control blood pressure, reduce brain edema, expand blood vessels, improve consciousness, and symptomatic support treatment. 3 days after the onset of the disease, h... This is the first report that posterior reversible encephalopathy syndrome is caused by a thrombocytopenia regimen, and our case highlights the pathogenic role of a thrombocytopenia regimen in posteri...

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.

Docetaxel-related adverse events (AEs) such as neutropenia and febrile neutropenia (FN) can be life-threatening. A previous in vivo study raised the hypothesis that the castration status affects the r... We retrospectively analyzed the records of 265 mPCa patients treated with docetaxel, comprising 92 patients with metastatic hormone-sensitive prostate cancer (mHSPC) and 173 patients with metastatic c... The rate of patients who received primary prophylaxis against neutropenia was higher in those with the mHSPC compared with those with the mCRPC (7.5% vs. 33%, p < 0.001). Among the patients without pr... Castration status did not affect the risk of severe neutropenia or FN in mPCa patients treated with docetaxel regardless of the disease state. Failure to provide primary prophylaxis and advanced patie...

A pharmacometrics model to define docetaxel target in early breast cancer.

We aimed to study the relation between pharmacokinetics (PK) and pharmacodynamics (PD) of docetaxel in early breast cancer and recommend a target exposure.... A PK/PD study was performed in 27 early breast cancer patients treated with doxorubicin and cyclophosphamide for 4 cycles followed by 4 cycles of docetaxel 75-100 mg/m... Docetaxel clearance showed no change over the 4 treatment cycles, but a gradual increase in the volume of distribution was observed. One third of the patients had at least 1 dose reduction of docetaxe... We report for the first time a relation between docetaxel exposure and toxicity and recommend specific targets of drug exposure with implications for the clinical management of early breast cancer pat...

SNHG1 opposes quiescence and promotes docetaxel sensitivity in prostate cancer.

A majority of prostate cancer cells are in a non-proliferating, G... Publically available, anonymous, clinical data was obtained from cBioPortal for analysis. RNAi and prostate cancer cell lines were utilized to investigate SNHG1 in vitro. We measured G... We discovered that in prostate cancer patients from The Cancer Genome Atlas (TCGA) data set, high SNHG1 expression in localized tumors correlated with reduced progression-free survival, and in a data ... Overall, these results indicate SNHG1 has complex roles in prostate cancer, as it stimulates cell cycle entry and disease progression, but sensitizes cells to docetaxel treatment....

Optimal exposure to docetaxel in adjuvant chemotherapy for early-stage breast cancer.

Drug-induced neutropenia is the main reason for the dose limitation of docetaxel in patients with breast cancer. The area under the drug concentration-time curve (AUC) of docetaxel is associated with ... Docetaxel plasma concentration, demographics, clinical data, and related laboratory data were collected. PopPK analyses were performed using a nonlinear mixed-effect modelling program. The docetaxel A... Among the 70 participants, 47 (67.1%) developed severe neutropenia. The PopPK analysis showed that the typical drug clearance (CL) rate was 37.4 L/h. Age was a significant covariate of CL rate, and as... We developed a docetaxel PopPK model for patients with early-stage breast cancer. Age and AST and ALB levels were significant covariates. AUC estimated using the MAPB method can predict the toxicity o... Chinese Clinical Trial Center Registry (ChiCTR2200056460)....